Mylonas Konstantinos S, Angouras Dimitrios C
Department of Cardiac Surgery, Onassis Cardiac Surgery Center, 17674 Athens, Greece.
Department of Cardiac Surgery, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece.
J Clin Med. 2023 Nov 13;12(22):7063. doi: 10.3390/jcm12227063.
This review explores the use of bioprosthetic valves for the lifetime management of patients with aortic stenosis, considering recent advancements in surgical (SAV) and transcatheter bioprostheses (TAV). We examine the strengths and challenges of each approach and their long-term implications. We highlight differences among surgical bioprostheses regarding durability and consider novel surgical valves such as the Inspiris Resilia, Intuity rapid deployment, and Perceval sutureless bioprostheses. The impact of hemodynamics on the performance and durability of these prostheses is discussed, as well as the benefits and considerations of aortic root enlargement during Surgical Aortic Valve Replacement (SAVR). Alternative surgical methods like the Ross procedure and the Ozaki technique are also considered. Addressing bioprosthesis failure, we compare TAV-in-SAV with redo SAVR. Challenges with TAVR, such as TAV explantation and considerations for coronary circulation, are outlined. Finally, we explore the potential challenges and limitations of several clinical strategies, including the TAVR-first approach, in the context of aortic stenosis lifetime management. This concise review provides a snapshot of the current landscape in aortic bioprostheses for physicians and surgeons.
本综述探讨了生物人工心脏瓣膜在主动脉瓣狭窄患者终身管理中的应用,同时考虑了外科生物人工心脏瓣膜置换术(SAV)和经导管生物人工心脏瓣膜(TAV)的最新进展。我们研究了每种方法的优势和挑战及其长期影响。我们强调了外科生物人工心脏瓣膜在耐用性方面的差异,并考虑了新型外科瓣膜,如Inspiris Resilia、Intuity快速部署瓣膜和Perceval无缝合生物人工心脏瓣膜。讨论了血流动力学对这些人工心脏瓣膜性能和耐用性的影响,以及在外科主动脉瓣置换术(SAVR)期间扩大主动脉根部的益处和注意事项。还考虑了诸如Ross手术和Ozaki技术等替代手术方法。在解决生物人工心脏瓣膜失效问题时,我们比较了SAV中的TAV与再次SAVR。概述了TAVR的挑战,如TAV取出和冠状动脉循环的注意事项。最后,我们探讨了在主动脉瓣狭窄终身管理背景下几种临床策略的潜在挑战和局限性,包括优先采用TAVR的方法。这篇简明综述为内科医生和外科医生提供了主动脉生物人工心脏瓣膜当前情况的简要概述。